Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2023-08-28 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Nature Cancer Publishes Results of PXS Garvin Collaboration 3 pages 266.3KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 29 August 2023 from Pharmaxis Ltd announcing preclinical research results related to their cancer drug PXS-5505. It discusses scientific findings, collaboration with the Garvan Institute, and references publications in scientific journals. There is no financial data, regulatory filing, or detailed financial performance information. The document is a public announcement of research progress and scientific collaboration rather than a financial report, regulatory filing, or management discussion. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is a press/media release announcing scientific research results and company progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-08-28 English
Preliminary Final Report 67 pages 2.5MB
Annual Report Classification · 100% confidence The document is a detailed filing from Pharmaxis Ltd dated 28 August 2023. It references an Appendix 4E Preliminary Final Report and a 2023 Directors’ Report and Annual Financial Report for the year ended 30 June 2023. The content includes comprehensive financial statements, directors' report, remuneration report, corporate governance, senior management details, operating and financial review, and auditor's report. The document contains actual financial data, audited consolidated financial statements, and extensive management commentary. This matches the characteristics of an Annual Report (10-K equivalent) rather than a mere announcement or a regulatory filing. The length (15,000 characters) and detailed financial and management information confirm it is the full annual report document, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2023
2023-08-27 English
Change in substantial holding 7 pages 946.2KB
Regulatory Filings Classification · 70% confidence The document text is almost entirely composed of placeholders indicating omitted pictures, with no substantive textual content available for analysis. The metadata indicates the document length is 15,000 characters, which is substantial, but the actual text content is not provided. Without any textual clues such as report titles, fiscal periods, regulatory references, or financial data, it is impossible to classify this document as a specific report type like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or others. Given the lack of content and the fallback rule, the best classification is Regulatory Filings (RNS), which serves as a general category for filings that do not fit other specific types or when insufficient information is available.
2023-08-13 English
PXS to Receive Prepayment of 2023 Research Tax Incentive 2 pages 193.5KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 8 August 2023 announcing that Pharmaxis Ltd has executed a loan facility agreement to receive an advance on its expected 2023 R&D tax incentive claim. The content focuses on a financing arrangement related to the company's anticipated tax incentive, describing the loan terms, purpose, and company background. There are no financial statements, detailed financial results, or comprehensive report data included. The document is essentially an announcement of a capital/financing update rather than a full financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-08-07 English
Notification of cessation of securities - PXS 4 pages 23.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of performance rights securities for PHARMAXIS LTD. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain securities. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an official notification related to securities status changes. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-08-07 English
Application for quotation of securities - PXS 6 pages 27.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a formal announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. It does not contain financial statements or performance data, nor is it a report or presentation. Therefore, it fits the category of Share Issue/Capital Change announcements.
2023-08-07 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.